retatrutide human trials Eli Lilly infiltrates anti-obesity market as Phase III trial for begins Retatrutide UK: 2026 Clinical Trial

It is a triple agonist that also activates GIP and glucagon receptors, giving it metabolic advantages that semaglutide cannot match

For eligible children with obesity, it is advisable to initiate treatment as early as possible

Blue KCs coverage of GLP-1s relies squarely on our strategy to balance member need, product supply issues, and cost containment

Product choice may depend on internal project planning, research governance, storage procedures and purchasing approval

glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial